Shelton Earp

Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.

Human epidermal receptor-2 expression in prostate cancer.

The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.

Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation.

Transactivation of the EGF receptor: is the PDGF receptor an unexpected accomplice?

Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer.

The C-mer gene is induced by Epstein-Barr virus immediate-early protein BRLF1.

Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy.

Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox.

The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells.

Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells.

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.

The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation.

Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones.

Research for North Carolina: The University Cancer Research Fund.

The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.

ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.

TAM receptors are dispensable in the phagocytosis and killing of bacteria.

A novel role for c-Src and STAT3 in apoptotic cell-mediated MerTK-dependent immunoregulation of dendritic cells.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Increased hematopoietic cells in the mertk-/- mouse peritoneal cavity: a result of augmented migration.

Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

UNC1062, a new and potent Mer inhibitor.

Molecular Pathways: MERTK Signaling in Cancer.

UNC569, a novel small molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.

Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.

Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.

Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding.

Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC.

Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.

Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.

Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.

Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors.

Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.

The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.

Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing.

Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response.

Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking.

Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays.

MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.

MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type Family Members.

ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK).

MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression.

Beyond growth signaling: apoptotic sensor MERTK activates AKT by a novel mechanism.

Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.

TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.

Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology.

Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications.